Related Experiment Videos
Muramyl tripeptide: an effective immunotherapy in the surgical setting for pediatric abdominal neoplasms
Abstract:
A potential complication of intraperitoneal neoplasms is the occurrence of peritoneal metastases. This experiment hypothesizes that resident peritoneal macrophages, activated by muramyl tripeptide (MTP-PE), will destroy peritoneal tumor. MTP-PE is a lipophilic derivative of the mycobacteria cell wall component responsible for induction of cellular immunity and activation of macrophages to a tumoricidal state. A transplantable murine fibrosarcoma, MCA-F was utilized. Murine hosts were challenged intraperitoneally with 5 X 10(3) MCA-F cells. Treatment with MTP-PE micelles or liposome-encapsulated MTP-PE was initiated 48 hours prechallenge and on the day of tumor challenge and continued at 72 hour intervals for the subsequent 21 days. Hosts were observed for survival. At 45 days after tumor challenge, all untreated control animals had succumbed to overwhelming neoplastic disease. In contrast, 30% of the mice treated with liposome-encapsulated MTP-PE (P less than .05) and 50% of the animals treated with MTP-PE micelles (P less than .001) remained alive at 60 days. Followed for 120 days, 20% of MTP-PE micelle treated mice are long-term survivors. These results suggest that control of intraperitoneal seedings may be achieved with MTP-PE when the tumor burden is small.
Insights
Muramyl tripeptide (MTP-PE) activates macrophages to combat peritoneal tumors. This immunotherapy shows promise in controlling small intraperitoneal tumor burdens, with micelle and liposome formulations improving survival rates in mice.
Area of Science:
- Immunology
- Oncology
- Drug Delivery Systems
Background:
- Peritoneal metastases are a significant complication of intraperitoneal neoplasms.
- Resident peritoneal macrophages play a role in immune surveillance within the peritoneal cavity.
Purpose of the Study:
- To investigate the efficacy of muramyl tripeptide (MTP-PE) in activating peritoneal macrophages to destroy peritoneal tumors.
- To evaluate the therapeutic potential of MTP-PE micelles and liposome-encapsulated MTP-PE against intraperitoneal fibrosarcoma in a murine model.
Main Methods:
- A transplantable murine fibrosarcoma (MCA-F) model was used, with hosts challenged intraperitoneally.
- Treatment with MTP-PE micelles or liposome-encapsulated MTP-PE was administered pre- and post-tumor challenge over 21 days.
- Host survival was monitored for up to 120 days.
Main Results:
- All untreated control mice succumbed to neoplastic disease by 45 days.
- Treatment with liposome-encapsulated MTP-PE resulted in 30% survival at 60 days (P < .05).
- Treatment with MTP-PE micelles led to 50% survival at 60 days (P < .001), with 20% long-term survivors at 120 days.
Conclusions:
- MTP-PE, particularly in micelle or liposomal formulations, can activate macrophages to exert anti-tumor effects against peritoneal neoplasms.
- These findings suggest that MTP-PE immunotherapy may be effective in controlling early-stage or small tumor burdens of intraperitoneal cancers.